Allogeneic Transplantation
6
2
2
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
Improve Outcomes for Older Allogeneic Transplant Recipients
Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation